The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Related News Articles

Headline
The AHA urged the Department of Commerce Oct. 17 to take a balanced approach to ensuring dependable and affordable access to personal protective equipment,…
Headline
The AHA’s Association for Health Care Resource & Materials Management has created a webpage featuring resources on tariffs impacting the health care supply…
Headline
The White House Oct. 10 announced it reached an agreement with AstraZeneca to align drug prices with the lowest paid by other developed nations, also known as…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…